Review
Accepted on 24 Dec 2024
Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1523518
Type at least 3 characters
6,832 articles
Articles
Review
Accepted on 24 Dec 2024
Effects of Macrophages in OSCC Progression
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1517886
Original Research
Accepted on 24 Dec 2024
Bibliometric Analysis of Targeted Immunotherapy for Osteosarcoma-Current Knowledge, Hotspots and Future Perspectives
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1485053
Original Research
Accepted on 24 Dec 2024
Identification of Hub Genes and immune-related Pathways in Acute Myeloid Leukemia: Insights from Bioinformatics and Experimental Validation
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1511824
Methods
Accepted on 24 Dec 2024
TMBocelot: an Omnibus statistical Control modeL Optimizing the TMB Thresholds with systematic measurement errors
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1514295
Original Research
Accepted on 24 Dec 2024
In vitro functional validation of anti-CD19 chimeric antigen receptor T cells expressing lysine-specific demethylase 1 short hairpin RNA for the treatment of diffuse large B cell lymphoma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1521778
Original Research
Accepted on 24 Dec 2024
Construction of an Anaplastic Thyroid Cancer Stratification Signature to Guide Immune Therapy Selection and Validation of the Pivotal Gene HLF through In Vitro Experiments
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1478904
Review
Published on 24 Dec 2024
Crosstalk between thyroid CSCs and immune cells: basic principles and clinical implications
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1476427
- 216 views
Original Research
Published on 24 Dec 2024
The systemic inflammation response index (SIRI) predicts survival in advanced non-small cell lung cancer patients undergoing immunotherapy and the construction of a nomogram model
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1516737
- 218 views
Original Research
Published on 24 Dec 2024
The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1503316
- 141 views
Brief Research Report
Published on 24 Dec 2024
Ionizing radiation improves skin bacterial dysbiosis in cutaneous T-cell lymphoma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1520214
- 135 views
Original Research
Published on 24 Dec 2024
Single-cell Atlas reveals core function of CPVL/MSR1 expressing macrophages in the prognosis of triple-negative breast cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1501009
- 145 views
Original Research
Published on 24 Dec 2024
Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1524629
- 113 views
Case Report
Published on 24 Dec 2024
Case report: Complete response in TMB-H advanced uterine clear cell carcinoma: a case analysis of paclitaxel albumin-bound combined with PD-1/CTLA-4 bispecific antibody
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1486200
- 131 views
Original Research
Published on 24 Dec 2024
Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1502936
- 126 views
Original Research
Accepted on 23 Dec 2024
Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1474442